# Personalized Antisense Oligonucleotide Therapy for a Participant With TARDBP ALS

> **NCT07703462** · PHASE1,PHASE2 · ENROLLING_BY_INVITATION · sponsor: **n-Lorem Foundation** · enrollment: 1 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis (ALS)

## Interventions

- **DRUG:** nL-TARDB-002

## Key facts

- **NCT ID:** NCT07703462
- **Lead sponsor:** n-Lorem Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-12
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 1 (ESTIMATED)
- **Last updated:** 2026-07-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07703462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07703462, "Personalized Antisense Oligonucleotide Therapy for a Participant With TARDBP ALS". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07703462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*